Are vaginal microbiome tests the next frontier—or just great marketing?
Industry Buzz
I think vaginal microbiome testing is a double-edged sword... There is such evolving nuance in what constitutes a ‘healthy’ vaginal microbiome—and how that differs depending on racial and geographic factors.
—Laura Ensign, PhD, professor in the biomedical engineering program at Johns Hopkins University
Vaginal microbiome testing has emerged as a new frontier in women’s health, reflecting a broader movement toward personalized, data-driven care. []
Promoted by an increasing number of startups and diagnostic companies, these tests claim to offer insights into vaginal health, fertility, and infection risk through sequencing-based analysis of the vaginal flora. []
But a critical question remains: How much of this innovation is grounded in rigorous science—and how much is outpacing clinical evidence?
What is vaginal microbiome testing?
In healthy individuals, the vaginal microbiome is typically dominated by Lactobacillus, bacteria that produce lactic acid, helping to maintain a healthy acidic pH range. [] A healthy pH (around 3.5 to 4.5) is critical for inhibiting the growth of pathogenic organisms. Changes in vaginal pH levels, frequently caused by decreased lactic acid, are linked to vaginal dysbiosis and have been found in those with chlamydia, bacterial vaginosis, and vulvovaginal candidasis.
The testing process usually involves a self-collected vaginal swab, which is sequenced to identify microbial species and their relative abundance. [] Results often include a personalized “health score” and targeted probiotic or lifestyle recommendations.
Some platforms claim to detect hundreds of microbial strains, offering a level of granularity far beyond traditional cultures or basic diagnostics. []
Related: 3 major shifts in women’s health you probably weren't expecting—and can't afford to missThe science behind these tests
Emerging evidence supports the potential clinical value of understanding vaginal microbial composition.
A recent review published in Frontiers in Cellular and Infection Microbiology suggests that the vaginal microbiome could be a promising diagnostic marker in conditions like BV and pregnancy-related complications such as preterm birth and infertility. [] Additionally, ongoing research has been instrumental in defining “community state types” (CSTs) and exploring their associations with gynecologic and reproductive health risks. [][]
“I think vaginal microbiome testing is a double-edged sword,” Laura Ensign, PhD, a professor at Johns Hopkins University and the co-founder of Freya Biosciences, tells MDLinx. “There are certainly cases, like the tests available for endometrial and vaginal microbiome sequencing, where there is some potential clinical value, such as determining when might be unfavorable for embryo transfer in IVF.”
Some commercial platforms have begun validating their methodologies. For example, Evvy, a leading at-home testing company, reports over 90% specificity in microbial identification using metagenomic sequencing. [] Yet experts caution that testing alone offers limited utility without proven ways to act on the results.
“The big issue is that we do not have much available in terms of meaningfully changing the vaginal microbiome composition in a robust manner,” Dr. Ensign explains. “Thus, ‘bad news’ is often just that—and probably causes more emotional distress than clinical value.”
There is such evolving nuance in what constitutes a ‘healthy’ vaginal microbiome—and how that differs depending on racial and geographic factors.
—Laura Ensign, PhD
The limitations of these tests
Despite these promising developments, vaginal microbiome testing is not yet considered a validated diagnostic tool in routine clinical practice.
Key limitations remain: a lack of standardization across laboratories, uncertain clinical interpretation of results, limited evidence of effective interventions, and minimal regulatory oversight. []
The clinical bottom line is one of cautious optimism. Vaginal microbiome testing holds genuine potential, particularly in research settings or for patients with chronic or recurrent symptoms for whom traditional diagnostics have failed.
However, until large-scale, peer-reviewed studies clearly define actionable diagnostic and therapeutic pathways, clinicians should approach these tests carefully.
It’s essential to counsel patients on current limitations, avoid unnecessary treatments, and resist overinterpreting results that have not yet been clinically validated.
Related: Finally, a first step in taking women's health seriously